



Essai Clinique

Généré le 18 mai 2024 à partir de

Titre	Étude de phase III randomisée, multicentrique, à double insu et contrôlée par placebo sur l'efficacité et l'innocuité du trastuzumab emtansine en association avec l'atézolizumab ou un placebo chez les patients atteints d'un cancer du sein localement avancé positif pour le récepteur 2 du facteur de croissance épidermique humain et pour le ligand 1 de mort programmée ou d'un cancer du sein métastatique, ayant reçu un traitement antérieur à base de trastuzumab (avec ou sans pertuzumab) et de taxane
Protocole ID	KATE3
ClinicalTrials.gov ID	NCT04740918
Type(s) de cancer	Sein
Phase	Phase III
Stade	Maladie avancée ou métastatique
Type étude	Clinique
Médicament	Trastuzumab emtansine en association avec l'atézolizumab ou un placebo
Institution	CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE  HOPITAL FLEURIMONT 3001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4
Ville	
Investigateur principal	Dr Michel Pavic
Coordonnateur	Michelle Roy 819-346-1110 poste 12848
Statut	Fermé
But étude	This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or MBC. Participants must have progressed either during or after prior trastuzumab- (+/- pertuzumab) and taxane-based therapy for LABC/MBC; or during (or within 6 months after completing) trastuzumab- (+/-pertuzumab) and taxane-based therapy in the neoadjuvant and/or adjuvant setting.
Critères d'éligibilité	• HER2+ and PD-L1+ locally advanced (LABC) or metastatic breast cancer (MBC) • Progression must have occurred during most recent treatment for LABC/MBC or during, or within 6 months after completing, neoadjuvant and/or adjuvant therapy • Prior treatment with trastuzumab (+/- pertuzumab) and taxane in the neoadjuvant and/or adjuvant, locally advanced, or metastatic setting • No more than two prior lines of therapy in the metastatic setting • Measurable disease per RESIST version 1.1 • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 • Life expectancy $\geq$ 6 months • Adequate hematologic and end-organ function • For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs • For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm

Critères d'exclusion

- Prior treatment with trastuzumab emtansine in metastatic setting
- History of exposure to cumulative doses of anthracyclines
- Symptomatic or actively progressing central nervous system (CNS) metastases; asymptomatic CNS lesions ≤ 2 cm without clinical requirement for local intervention or asymptomatic patients with treated CNS lesions are eligible
- Current Grade ≥ 3 peripheral neuropathy
- Cardiopulmonary dysfunction
- History of malignancy within 5 years prior to initiation of study treatment, with the exception of the cancer under investigation and malignancies with a negligible risk of metastasis or death
- History of leptomeningeal disease
- Active or history of autoimmune disease or immune deficiency
- Active hepatitis B, hepatitis C and/or tuberculosis
- Prior allogeneic stem cell or solid organ transplantation
- Receipt of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, during treatment, or within 5 months following the last dose of study treatment
- Pregnancy or lactation